Tumor-infiltrating lymphocyte (TIL) therapy is a promising new approach to cancer therapy that harnesses the body’s own immune system to treat diseases like melanoma, a type of skin disease, an expert said.
Health Professionals
Low Neutrophil-Lymphocyte Ratio Linked to Better Survival in Some Melanoma Cases
Baseline neutrophil-lymphocyte ratio (NLR) is a significant predictor of disease progression and overall survival (OS) in patients with metastatic melanoma undergoing programmed cell death receptor-1 (PD-1) and its ligand (PD-L1) blockade therapy, according to study results published in Melanoma Research.
Dr Moreno on the Pharmacodynamics of CLN-619 in Advanced Solid Tumors
Victor Moreno, MD, PhD, medical oncologist, director, Clinical Research, START Madrid-Fundación Jimenez Diaz (FJD), discusses insights into the pharmacodynamic data for CLN-619, a novel humanized IgG1 antibody designed to bind to MICA and MICB, in patients with advanced solid tumors. Findings were presented by Moreno and colleagues during the 2024 SITC Annual Meeting.
Moffitt Study Shows Immune Structures in Melanoma Could Help Predict Patient Survival
TAMPA, Fla. — A new study has found that certain immune structures may be linked to better survival in patients with melanoma, the deadliest form of skin cancer. The study, led by researchers at Moffitt Cancer Center in collaboration with investigators at UPMC Hillman Cancer Center, was published in the Journal for ImmunoTherapy of Cancer.